Published on Meeting Library (http://meetinglibrary.asco.org) Home > 130361-144

Primary clinical use of the sono-photo-dynamic therapy for advanced esophagocadiac and gastric adenocarcinoma. Meeting: 2014 ASCO Annual Meeting Category: Gastrointestinal (Noncolorectal) Cancer Subcategory: Esophageal or Gastric Cancer Session Type and Session Title: This abstract will not be presented at the 2014 ASCO Annual Meeting but has been published in conjunction with the meeting. Abstract Number: e15024 Citation: J Clin Oncol 32, 2014 (suppl; abstr e15024) Author(s): Lucy Qing Li, Xiaohuai Wang, Iris Wenyin Zhang, Douglas Mitchell; EEC Bio-tech Co Ltd, Guangzhou, China; Liu Hua Qiao Hospital, Guangzhou, China; Southern Medical University Renkang Hospital, Dongguan, China; Science Group Pty Ltd, Melbourne, Australia Background: Sonodynamic therapy (SDT), a procedure related with photodynamic therapy, is a promising new modality for treating deep-seated cancer. Two new chlorophyll derived sono-photo-sensitizing agents, along with ultrasound equipment for systemic treatment (SDT), have been developed by EEC Biotech and all approved by regulator for safety on human. Animal studies demonstrate that the sensitizers are specifically absorbed into tumor cells and SDT does inhibit growth of mouse S-180 sarcoma. An in vitro experiment with human breast and lung cancer cell-lines showed that SDT was strongly synergetic with chemotherapy. We reported before about using sono-photo-dynamic therapy (SPDT, a combination therapy of SDT and PDT ) as a supplementary or salvage treatment in advanced breast cancer, and now report some positive results in advanced esophageal and gastric cancer by using SPDT. Methods: Seven patients were pathologically proven advanced esophagocadiac and gastric adenocarcinoma. 3 patients had conventional chemotherapy before. With SPDT, Patients took the sensitizers sublingually on day 1 and 2; red light and multiple ultrasound transducers irradiate tumor area and whole body on day 4 to 6. The treatment was repeated. All patients had concurrent chemo

with range from moderate to 1/2 conventional dosages selected to keep side effects at grade II or better. 2 patients received local radiation therapy as well. Results: The seven patients achieved CR 3(42.8%), PR 3 (42.8%), MR 1, with an overall response rate of 85%. The main SPDT side effects were easily reversible mild pain in tumor areas, tiredness and weakness. There was no skin sensitivity. SPDT/dose controlled chemo was well tolerated, even along with the radiation therapy. Conclusions: These preliminary data suggest that SPDT has almost no toxicity, but may dramatically enhance the conventional therapeutic efficacy in advanced refractory esophagocadiac and gastric adenocarcinoma. SPDT has a good trend to be a new systemic, low toxicity tumor therapy and merit for further investigation.

Source URL: http://meetinglibrary.asco.org/content/130361-144